Join the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationRob Reid, 21 February 2025
Exceptions and modifications to the EU guidance on good pharmacovigilance practices that apply to UK MAHs and the MHRA
This regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.
Updates on the ACT EU initiative, CTIS and the clinical trials landscape in the EU
The newsletter for patients, consumers and healthcare professionals
Manufacturers can request advice on their medical device clinical development programme
Guidance for Institutions and IRBs OHRP's and FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidance describes OHRP's and FDA's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.
This guidance clarifies the expectations on the application of the EU guidance on good pharmacovigilance practices (GVP) - guidance notes updated.
Link to Expression of Interest form added 10th Feb. 2025
Confirmation of when it is expected to come into force.